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The Art and Science of Thyroid Surgery in the Age of Genomics:
100 years after Theodor Kocher
Genomik Çağında Tiroid Cerrahi Sanat ve Bilimi: Theodor Kocher’den 100 Sene Sonra
Seza Gulec, MD, FACS
Florida International University Herbert Wertheim College of Medicine, Departments of Surgery and Nuclear Medicine, Miami, USA

Abstract
Cancer is a disorder of the genome. The thyroid cancer genome is being decoded. Recent studies have identified a mutation
or a genetic alteration in 95% of thyroid cancers. The National Cancer Institute initiated the Cancer Genome Atlas project in
2006 to catalogue genetic mutations associated with cancer, using genome sequencing and bioinformatics. The project has
expanded to carry out genomic characterization and sequence analysis of thyroid cancer. The concept of risk stratification
based on traditional parameters will soon vacate their role for clear molecular markers of non-invasive/focal, invasive/
metastatic and systemic stages/phases of neoplastic disorder. A refined classification scheme based on genomics and its
phenotypic expressions will accurately reflect the biologic differences between the different morphologic definitions we use
today. Tumor differentiation/de-differentiation, and clinical behavior of an individual cancer will be defined by molecular
markers, in addition to standard morpho-pathology. Empiricism in science of medicine and surgery has acquired a new
method for testing the appropriate treatment for individual patients; that is molecular pathology, governed by genomics. The
technology is present and rapidly evolving. The surgeons will determine the extent of interventions with molecular evidence
and guidance.
Keywords: Genomics, thyroid cancer, thyroidectomy, radioactive iodine, beta knife

Öz
Tiroid cerrahisinin bilimsel temelleri Theodor Kocher tarafından tanımlandı. Bu ustayı 100 yıl önce uğurladık. Tirod kanseri
cerrahisi ve tiroid kanseri hastalarının tedavisi ile tartışmalar süregelmektedir. Konunun mihengi açıkçası ilk aşama cerrahi
tedavinin boyutudur. Cerrahi tedaviyi izleyen kısa ve uzun dönemde uygulanabilecek tedaviler, yararlanılabilecek tetkik
ve görüntüleme yöntemleri de ilk cerrahi tedavinin çerçevesiyle alakalıdır. Amerikan Tiroid Birliği’nin 2015 basımı tedavi
kılavuzu dahil olmak üzere, geleneksel olarak tiroid kanserinin klinik değerlendirmesi morfolojik öğelere dayalı yapılır. Tümör
büyüklüğü, histolojik varyantlar ve hasta yaşı kriterleri cerrahi ve cerrahi sonrası girişimlerin boyutunu belirler. Kanser genomu
projesi kapsamında tiroid kanseri genom profili aydınlanmaya başladı. Hala birçok bilinmeyen olmakla birlikte bu konuda
bilgi birikimimiz hızla artıyor. İnce iğne biyopsisi materyalinde hastaların kromozom değişiklikleri ve nokta mutasyonları tespit
edilebilmekte, bu genomik değişikliklerin biyolojik anlamları araştırılabiliyor. Bu teknoloji hızla teşhis ve tedavi yönlendirilmesinde
kullanıma giriyor. Bundan böyle tedavi seçimlerinde genomik kılavuz ve yönlendirme kullanılacak. Bu makale cerrahi sanatının
mahir ustalarını ve cerrahi bilimindeki genomik devrimi selamlıyor.
Anahtar kelimeler: Genomik, tiroid kanseri, tiroidektomi, radyoaktif iyot, beta bıçak
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Kocher reported on approximately 5.000 operations with
a mortality of about 0.5%. When he started his work in
the 1870s, thyroid surgery was a high-risk procedure, with
an estimated mortality of 75% in 1872. Thyroid operations
were prohibited by the Academy of Medicine in France at
that time. Kocher was appointed to the Chair of Surgery in
Berne, Switzerland, in 1872, at the age of 31, and began his
influential work in thyroid surgery and medicine. His most
acclaimed achievement, his surgical technique, was marked
by meticulous care in dissecting and ligating blood vessels,
and precise dissection within the thyroid capsule (1). William
Halsted’s impression on Kocher’s surgical technique was/
is quite remarkable. Halsted described Kocher’s technique
as “neat and precise, operating in a relatively bloodless
manner, scrupulously removing the entire thyroid gland
doing little damage outside its capsule” (2). Kocher was
the first to describe the devastating complication(s) of total
extirpation of the thyroid gland. He also recognized the
underlying pathophysiologic changes in a diseased gland.
This was, in a sense, a “molecular vision.” He intuitively
contemplated that the growth of goiter nodules was an
early determined event in altered thyroid physiology, and
that the abnormal thyroid tissue was the source of a goiter
recurrence. He conceived the notion of autonomously
growing, focally distributed clusters of follicular cells in
nodular goiter. He, thus, advocated a total thyroidectomy
rather than selective removal of all thyroid nodules. Kocher
had realized that the so-called “subtotal” thyroidectomy,
leaving behind naturally growth-prone tissue, would lead to
goiter recurrence. The concept was called “Innere Chirurgie”
(internal surgery), a scientific surgical philosophy based on
biological considerations. This was the beginning of a new
epoch. The leading minds were Kocher in Berne, Halsted
in Baltimore, and Mikulicz (coined the term) in Krakau (3).
Despite impressive discoveries in surgical anatomy and
physiology, the onco-biology of neoplasia and the clinicopathologic characteristics of cancer were poorly understood
at Kocher’s time. Although Kocher had significant studies on
malignant tumors of the thyroid gland, the modern science
for cancer surgery was developed by William Halsted, who
championed a radical treatment approach for breast cancer.
Halsted’s idea was based on the premise that cancer had
a linear, step-wise growth fate and had to be be treated
with total extirpation of the organ along with its lymphatic
drainage network. This was believed to be necessary for
cure, and was adapted by many prominent surgeons.
This classic rationalistic philosophy in surgery dominated
the surgical world for years. Similarly, thyroid surgery for
cancer in the early post-Kocher era, called for an “en-block
resection” or “conventional radical neck dissection,” which
usually sacrificed the sternocleidomastoid muscle, internal
jugular vein, often the accessory nerve and sometimes the
marginal mandibular branch of the facial nerve. This was
all justified in the name of “cure. The core problem with
the rationalistic logical flow is the potential/possible flaw

The extirpation of the thyroid gland typifies,
perhaps better than any operation, the
supreme triumph of the surgeon’s art. A
feat which today can be accomplished by
any competent operator without danger of
mishap and which was conceived more than
one thousand years ago might appear an
unlikely competitor for a place in surgery so
exalted.
William Stewart Halsted
Milestones
Theodor Kocher died 100 years ago in 1917. Kocher is
considered the father of thyroid surgery (Figure 1).

Figure 1. Theodor Kocher

He received the 1909 Nobel Prize in Physiology or Medicine
for his work in the physiology, pathology and surgery of
the thyroid. A few weeks before his death, at the age of
76, he made his final appearance before the Swiss Surgical
Congress, reviewing his entire thyroid surgery experience.
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these potential source of misdiagnosis, when surgeon
to imager communication is still on-line, is important.
c) Post-ablation whole-body scan is an excellent extent
of disease evaluation tool. When the post-operative RAI
treatment is contemplated with an adjuvant intent, in
addition to the ablation objectives, RAI is aimed to target
residual disease or occult metastatic disease. When
the intent is adjuvant treatment, the risk stratification
becomes important in the selection of administered
activity of I-131. For remnant ablation purposes only, the
risk stratification has no bearing. The therapeutic effect
of I-131 works through the beta particles, thus, it should
be referred as “beta-knife.” Complete thyroidectomy, in
the strictest sense is only possible with surgical (cold steel
knife) thyroidectomy, followed by I-131 ablation (beta
knife) (Table 1).
The second half of the 20th century also witnessed the
birth of neo-empiricism in the acquisition and application of
scientific knowledge in medicine. The established dogmas
for radical surgical treatments were challenged, asking for
proof of efficacy based on outcome data. The new paradigm
was most palpable in the management of breast cancer
and thyroid cancer. The radical versus conservative surgery
argument was relatively easy to settle for breast cancer.
Bernard Fisher in the US and Umberto Veronesi in Italy ran
parallel trials resulting in clear demonstration of equivalency
of lesser surgery over radical operations. The problem with
thyroid cancer, however, remained unsettled. DTC was/is a
more indolent cancer with a much more protracted course.
Clinical trials with required statistical power were very difficult
to perform. The lack of definitive clinical trials unleashed a
never-ending controversy: Total thyroidectomy versus less
than total thyroidectomy. A new, rather ambiguous, lexis for
such operations entered into common use. Sub-total, neartotal thyroidectomy terms subsisted. At least for the sake
of clarification of the nomenclature, there should only be
two standard defining operations: Total thyroidectomy and
lobectomy. Total thyroidectomy is defined as the safe removal
of the thyroid gland with oncologically clean margins. If/
when eradication of all functioning thyroid tissue is the end
point, a cold steel knife is followed by the beta-knife.

in the original hypothesis. The entire chain of thoughts/
deductions, then, may lead to incorrect conclusions
(a-priori error). The outcomes, however, need to be tested
independently. (post-priori validation). This is the essence
of evidence-based, data-driving scientific methodology”.
George “Barney” Crile Jr. should be credited as the first
to challenge the radical thought process and action. He
was one of the first surgeons ever to promote the idea
that “the less surgery the better,” and he campaigned
vigorously for the abandonment of the radical operations.
His ideas on thyroid cancer surgery, and later breast cancer
surgery, were briskly opposed at the time, but eventually
succeeded (4). The new surgical vision was reluctantly,
but progressively accepted by the surgical community over
time, and has since, shaped the evolution of the philosophy
of surgical treatment.
Mid-century brought in a major innovation in the
management of thyroid cancer, the radioactive iodine
(RAI) treatment. First used by Samuel Seidlin (5), and
established as a fortitude by Bierwaltes (6), RAI became
an invaluable theranostic agent. The role for RAI in
the management of metastatic differentiated thyroid
cancer (DTC) became indisputable. Its utilization postoperatively, however, is still a matter of debate. As a guide
to perplexed; RAI treatment is given in 3 distinct settings
with distinct clinical indications (intents). 1) Ablation of
the remnant 2) Adjuvant treatment for residual disease or
occult metastatic disease 3) Therapy for known metastatic
disease. The term “ablation” specifically refers to first-line
RAI treatment following total surgical thyroidectomy. The
specific target of this treatment is normal residual thyroid
tissue- the remnant. The objectives of ablation are threefolds a) Ablation eradicates all the functioning thyroid
tissue. Thereby, thyroglobulin (Tg) becomes a highly
specific tumor marker. This simply facilitates the post-op
long-term follow-up. b) Ablation wipes out all focal normal
thyroid tissue left in-situ by the surgeon to avoid injury to
laryngeal nerves and parathyroid glands. From surgical
standpoint these small clusters of normal tissue remnants
are inconsequential, however, they appear as focal areas
of RAI uptake on future whole body imaging studies and
can easily be called as metastatic disease. Eradication of
Table 1. Radioactive iodine ablation objectives
RAI treatment intent

Target

Objectives

Ablation (First-line)

Remnant

1) Increase specificity of Tg monitoring,
2) Complete post-surgical staging
3) Identify/clear ambiguous foci of uptake

Adjuvant treatment (First-line)

1) Remnant,
2) Residual disease,
3) Occult metastatic disease

1) Ablation objectives,
2) Disease control

Therapy (Second-line)

1) Recurrent disease,
2) Metastatic disease

1) Disease control

RAI: Radioactive iodine, Tg: Thyroglobulin
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The Equipoise

It would have been easier to compose a narrative if the history
of thyroid surgery was a linear progression from a radical
operation towards a lesser one. The story, however, is more
confounded, partly due to the particular characteristics of the
disease and perhaps more so due to entrenched positions of
opinionated surgeons and oncologists, the very definition of
equipoise. All respectable institutions, and the thought leaders
in the field have made their contributions to the controversy
(10,11,12,13). Equipoise has become the standard of care in
the initial surgical treatment of thyroid cancer.
Authors on both sides of the debate have pointed out that
not all papillary carcinomas are equally indolent. Some
grow rapidly and progress more aggressively than others
often without obvious histological differences. Histological
variations such as the tall cell variant and columnar cell variant
have been identified, but many unusually malignant strains
cannot be morphologically distinguished as being different
from other examples of papillary carcinoma. Certain wellDTC will go on to have an aggressive course. They cannot
be histopathologically differentiated from those with typical
indolent course There appears not to have an exact way of
identifying those relatively infrequent differentiated cancers
that are destined to have a more malignant course. Despite
the significant progress in molecular pathology, the clinical
risk factors are currently the only stratification guide used
in thyroid cancer diagnosis and management. Proponents of
total thyroidectomy insist that the increase in complications is
minimal in the hands of an experienced surgeon. Proponents
of lobectomy point out that only one recurrent laryngeal
nerve is at risk when only one lobe of the thyroid is being
resected, thus the theoretical risk of nerve palsy is halved.
Disagreement over the merits of prophylactic central node
dissection has been argued in a similar context. Experience
suggests that the incidence of surgical complications may
not solely be dependent on the proficiency of the surgeon,
but also the extent of surgical procedure performed. So the
debate goes on, “equipoetically”.

An equipoise is a genuine disagreement among the experts
as to the optimal therapeutic approach in the management
of a particular condition. A true equipoise exists in the initial
treatment of DTC. There are two camps, represented by
two diametrically opposing philosophical thoughts. There
are those aggressively favor/defend the strategy of total
thyroidectomy with radioiodine ablation and periodic Tg
screening for “biochemical evidence of recurrence”. On the
opposite direction there are those taking a conservative stand
and prefer/defend performing thyroid lobectomy, when the
tumor is small and limited to one lobe of the gland. This
stance would automatically rule out post-surgical ablation as
well as “affect” the utility of Tg screening. This approach
relies more on clinical and ultrasound findings for “clinical
evidence of recurrence.” It is a true equipoise, as there is
genuine uncertainty in the expert medical community over
which approach is more beneficial. The option of lobectomy
(pertaining to tumors measuring 1cm or less), was proposed
in the 2009 American Thyroid Association (ATA) guidelines
(7). It became the recommended option for small tumors
in its 2015 edition (8). A more progressive conservatism is
endorsed in the 2010 version of the Japanese guidelines for
the treatment of thyroid tumors. In the Japanese guidelines,
the indications for a lobectomy were extended to tumors as
large as 4 cm, if they are limited to one lobe of the thyroid
with little or no extra-capsular invasion and no gross lymph
node involvement. As for papillary carcinoma less than 1cm,
some Japanese surgeons are proposing that observation
without surgical intervention may be sufficient (9).
The Japanese Guidelines, 2010
A) It is beyond dispute that patients with the following
characteristics are regarded as high-risk; tumor size
>5 cm, lymph node metastasis >3 cm, lymph node
metastasis extending to the internal jugular vein,
carotid artery, major nerves such as recurrent laryngeal
nerve, and prevertebral fascia, multiple and intensely
swollen lymph node metastasis, extrathyroidal
extension to the trachea and esophageal mucosa and
distant metastasis at diagnosis. Total thyroidectomy
is recommended for patients having one or more of
these characteristics (p.108)
B) Other patients are classified as a “gray-zone”, but
in these patients total thyroidectomy is recommended
if the tumor size is >4 cm, and clinical node metastasis
is detected (regardless of whether it is N1a or N1b)
(p.108)
C) Although further studies with larger patient
numbers and longer follow-up times are required,
observation without immediate surgery for papillary
microcarcinoma without metastasis or invasion can be
considered a reasonable option (p.121).

The American Thyroid Association Guidelines,
2015
The 2015 ATA guidelines is a 133 page document written in a
dissertation format. The rationale for each recommendation
was discussed, in detail, in a scholarly fashion. The section
on operative approach for a biopsy diagnostic for follicular
cell-derived malignancy (B7, Recommendation 35) defines
three categories.
The guideline committee states that in properly selected
low to intermediate risk patients, the extent of initial
thyroid surgery probably has little impact on disease
specific survival. While recurrence rates can be quite low in
properly selected patients, it is likely that the lowest rates of
recurrence during long term follow-up would be associated
with a total thyroidectomy. However, since salvage therapy
would be quite effective in the few patients that recur after
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This could help the plans for RAI therapy, facilitate followup strategies, and also may address suspicions of bilateral
disease (8). This conclusion returns us back to square one.
The accurate identification of individual patients who would
benefit from a limited intervention versus those who would
require the full artillery in hand remains challenged. Clearly,
a statistically insignificant, but clinically very important group
of outliers of risk categories defined using standard criteria
does exist. Particularly for DTC, morphology (or size)-alone
only partially explains the full onco-biology of the tumor.

American Thyroid Association 2015 Guidelines
A) For patients with thyroid cancer >4 cm, or with
gross extra-thyroidal extension (clinical T4), or clinically
apparent metastatic disease to nodes (clinical N1) or
distant sites (clinical M1), the initial surgical procedure
should include a near-total or total thyroidectomy
and gross removal of all primary tumor unless there
are contraindications to this procedure. (Strong
Recommendation, Moderate-quality evidence),
B) For patients with thyroid cancer >1 cm and <4
cm without extra-thyroidal extension, and without
clinical evidence of any lymph node metastases (cN0),
the initial surgical procedure can be either a bilateral
procedure (near-total or total thyroidectomy) or a
unilateral procedure (lobectomy). Thyroid lobectomy
alone may be sufficient initial treatment for low risk
papillary and follicular carcinomas; however, the
treatment team may choose total thyroidectomy to
enable RAI therapy or to enhance follow-up based upon
disease features and/or patient preferences. (Strong
Recommendation, Moderate-quality evidence),
C) If surgery is chosen for patients with thyroid
cancer <1 cm without extra-thyroidal extension
and cN0, the initial surgical procedure should be a
thyroid lobectomy unless there are clear indications
to remove the contralateral lobe. Thyroid lobectomy
alone is sufficient treatment for small, unifocal, intrathyroidal carcinomas in the absence of prior head
and neck irradiation, familial thyroid carcinoma, or
clinically detectable cervical nodal metastases (Strong
Recommendation, Moderate-quality evidence).

Risk Stratification and Staging of Thyroid Cancer
All cancers present as either localized or at an advanced/
metastatic stage, as does the thyroid cancer. The existing
paradigm equates metastatic stage to a systemic disorder.
The established staging system has become ingrained in
our culture. Some of the seemingly “self-evident” concepts
require revision. The extent of disease has been defined
by the TNM system, and stages have been determined
by outcome statistics. For DTC, patients younger than 45,
are assigned to stage II despite the presence of remote
metastatic disease (Table 2). A 2016 consensus report
based on a review of 9484 patients from 10 institutions
proposed a change in the cutoff age in the current American
Joint Committee on Cancer/Union for International Cancer
Control staging system from 45 years to 55 years. This
change is estimated to lead to a down-staging of 12% of
patients, and would improve the statistical validity of the
existing model. Such a change may be clinically relevant
for thousands of patients worldwide by preventing overstaging of patients with low-risk disease while providing a
more realistic estimate of prognosis for those who remain
high risk (14). The current paradigm has been inadequate
to resolve the growing controversies. There does not
appear to be a magic age cut-off that dicotomizes the

thyroid lobectomy, a conservative management approach
to up front surgery accepting a slightly higher risk of locoregional recurrence is an acceptable management strategy.
The guideline committee further stated that a more
selective use of RAI coupled with a greater reliance on neck
ultrasound and serial serum Tg measurements for detection
of recurrent disease is likely to significantly decrease the
mandate for total thyroidectomies in low and intermediate
risk patients done solely to facilitate RAI remnant ablation
and follow-up. Near-total or total thyroidectomy is
necessary if the overall strategy is to include RAI therapy
postoperatively, and thus is recommended if the primary
thyroid carcinoma is >4 cm, there is gross extra-thyroidal
extension, or regional or distant metastases are present.
For tumors that are between 1 and 4 cm in size, either a
bilateral thyroidectomy (total or near-total) or a unilateral
procedure (thyroid lobectomy) may serve as the surgical
platform for an overall treatment plan. Older age (>45
years), contralateral thyroid nodules, a personal history of
radiation therapy to the head and neck, or familial DTC
may be criteria for recommending a bilateral procedure.

Table 2. Staging of thyroid cancer
Papillary and follicular thyroid cancer (age <45 y)
Stage

T

N

M

I

Any T

Any N

M0

II

Any T

Any N

MI

Papillary and follicular thyroid cancer (age ≥45 y)
Stage

T

N

M

I

T1

N0

M0

II

T2

N0

M0

III

T3

N0

M0

T1-3

N1a

M0

T4a

N1b

M0

IVB

T4b

Any N

M0

IVC

Any T

Any N

M1

IVA
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patients into distinct risk categories. A remote metastatic
disease may not be the ultimate grave sign. There may
be another “phase” in cancer, besides the T, N, and M
extensions, that has not been factored-in current disease
state definitions. There could be a metabolic switch
converting cancer into a “systemic disorder”. There may
be a difference between a widespread disease and a
systemic disorder, which would define/explore the cancerhost metabolic interactions beyond mere expansion of
the cancer compartment. The metabolic and catabolic
changes associated with this change in phase have not
been identified. The road to fatality could be a phase
change during any given stage of cancer expansion. The
phase change could well be occurring in M0 disease or,
adversely develop at a seemingly early stage. The cellular/
subcellular dynamics of a true systemic disorder remain
undefined. The predicative molecular signatures of the
phase change has not been firmly defined. Ultimately, the
molecular profiling of individual cancers would be gauging
the credence of our knives. The foreseeable paradigm
change awaits the maturation of the genomics revolution.

The Age of Genomics
Cancer is a disorder of the genome.
Cancer is a disorder of the genome. The complete
genetic information of an organism is referred to
as genome. In all-encompassing terms, the genome
involves the genes (coding and the non-coding
sequences of the DNA), RNA(s), the process of
transcription and translation and their regulations. The
concept of regulation involves the genetic constituents
such as enhancer, promoter, transcription factors (TF),
RNA polymerase and mechanisms such as epigenetics.
Cancer is a complex expression of multiple genetic
and epigenetic alterations. There is an initiating
transformational mutational event, then a multitude
of genetic aberrations compose a cancer phenotype.
All cells throughout the body bear the same coding
sequence, yet, tissues and organs have distinct
morphology and functions. Normal tissue/organ
differentiation is simply a function of selective reading
of the genome by different cell types, most vivid in the
developing embryo. Cancer is a distinct differentiation,
or neo-differentiation, or dedifferentiation, in
reference to the normal tissue morphology/function.
As cells enter into a constitutive act of replication or
repeated cycles of growth and division, the central
hallmark of cancer, they also begin to assume distinct
phenotypes. This is the process of neo-differentiation.
The cells undergoing the neo-differentiation process
become committed to form different type of tissue
rather than the mature, conformal normal tissue. The
genome reading has a new translation.

Mol Imaging Radionucl Ther 2017;26(Suppl 1):1-9

The gene expression is modulated by “the switches”.
The orchestration of gene expression by “the switches”
involves multiple elements; The enhancer, a non-coding
DNA sequence where the TF bind. The binding of the
TF is arbitrated by a group of mediator proteins. The
enhancer sequence is located some distance upstream
of the promotor region, another non-coding DNA
sequence, to which RNA polymerase binds. All these
elements are also product of different set of coding
genes (subject to mutational changes). Moreover, if
a particular switch is deemed a compartment, the
intra-compartmental interactions are subject to the
chemical conformations altered by acetylation or
methylation reactions which are not mutational, but
referred to as “epigenetic” changes.
The thyroid cancer genome is being decoded. Recent
studies have identified a mutation or a genetic alteration
in 95% of thyroid cancers. The National Cancer Institute
initiated the Cancer Genome Atlas (TCGA) project in 2006
to catalogue genetic mutations associated with cancer,
using genome sequencing and bioinformatics. The project
has expanded to carry out genomic characterization and
sequence analysis of a multitude of cancers, including
thyroid cancer. Techniques involve gene expression
profiling, copy number variation profiling, single nucleotide
pleomorphism genotyping, genome wide DNA methylation
profiling, microRNA profiling, and exon sequencing of at
least 1,200 genes. TCGA is able to sequence the entire
genomes of tumors, including at least 6,000 candidate
genes and microRNA sequences.
The Integrated Genomic Characterization of Papillary
Thyroid Carcinoma (IGCPTC) study, the first systematic,
large scale and robust genomic analysis of thyroid cancer,
was published in October 2014 (15). The IGCPTC study
demonstrated the role of somatic genetic “alterations.” The
driving somatic genetic alterations included SSNVs, indels,
or fusions, in the mitogen-activated protein kinases (MAPK)
and PI3K pathways in PTC. The relatively low overall density
of somatic mutations was concluded to be the biological
basis for the indolent clinical behavior of PTC. It is evident
that the mutations and alterations are functions of time to
accompany the aging process. The prognostic importance
of age is a continuous variable, not determined by a cutoff value. New driver mutations were identified in PTC,
either entirely novel (EIF1AX), or novel alterations of known
drivers (RET, BRAF and ALK fusions) (Figure 1). As a result
of these discoveries, the “dark matter” of the PTC genome
has been reduced substantially from ∼25% to less than 4%,
which will have profound consequences for preoperative
cancer diagnosis of thyroid nodules as well as for surgical
and post-surgical treatment strategies. Molecular testing for
mutation hotspots, rearrangements, and gene expression
using fine-needle aspiration specimens has become an
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effective diagnostic tool to more precisely select patients
for an appropriate surgical procedure. Molecular testing
surely would reduce the number of thyroidectomies done
for benign nodules and tumors (16,17), and could guide
determine the extent of initial surgical procedure (i.e.,
lobectomy versus total thyroidectomy). Beyond the driver
mutations, it was also discovered that several individual key
genes [CHEK2, ATM, and Telomerase reverse transcriptase
(TERT)] and sets of functionally related genes (chromatin
remodeling) with alterations or expression patterns in
microRNA (miR-21 and miR-146b) define clinically-relevant
subclasses and may contribute to loss of differentiation and
tumor progression.
The IGCPTC study demonstrated striking signaling
differences in RAS- and BRAFV600E-driven PTCs. In
particular, BVL-PTCs signal preferentially through MAPK
while RL-PTCs signal through both MAPK and PI3K. The
relative simplicity of the PTC genome, with dominant
mutually exclusive driving events, together with the large
cohort and comprehensive data analyzed in this study
have led to clearly dissect these signaling differences. The
overreaching conclusion of the IGCPTC study was that RLPTCs and BVL-PTCs are fundamentally different in their
genetic, epigenetic, and proteomic profiles. Based on
the strength of the multidimensional genomic findings,
a clinico-pathologic reclassification of follicular-derived
thyroid lesions would be imperative (15).
The impact of different genomic markers on outcomes
opened a new field of controversy. Conflicting results
with BRAF (+) tumors have been reported for the past
10 years. An increasing number of studies, which include
meta-analyses, demonstrated an association between
the BRAF status and aggressive tumor behavior. Other
studies, however, have failed to confirm this data, and
this has resulted in uncertainty about the prognostic
value of BRAF mutations in PTC (18,19) It has become
clear that multiple genetic alterations contribute to
form an individual tumor phenotype and biology. A
progressive genomic instability leads to first functional,
then morphologic dedifferentiation. TERT promoter
mutations have been observed in 5% to 25% of DTC,
and it’s been reported that TERT promoter mutations
contribute to aggressive behavior in DTC (20,21,22).
These mutations have a significantly higher prevalence
in aggressive thyroid tumor types such as widely invasive
oncocytic carcinomas, poorly differentiated carcinomas,
and anaplastic thyroid carcinomas (ATC) (23). Similarly,
TP53 mutations are prevalent in advanced tumors with
a higher recurrence (24). A co-occurrence of multiple
mutations may define a more aggressive subgroup of
DTC (25).
The next-generation sequencing technology allows high
out-put genomic analysis. An innovative assay in thyroid
cancer ThyroSeq® - was developed for targeted mutation
detection by next generation sequencing technology in

fine needle aspiration and tissue samples. ThyroSeq v.2
next generation sequencing panel offers simultaneous
sequencing and detection in >1000 hotspots of 14 thyroid
cancer-related genes and for 42 types of gene fusions
known to occur in thyroid cancer (Table 3) (26). ThyroSeq is
being increasingly used to further narrow the indeterminate
category defined by cytology for thyroid nodules. From
a surgical perspective, obviously this provides prognostic
and predictive information as it relates to determination of
surgical strategy. Both the genomic analysis technology and
the data collection for the cancer genome atlas are rapidly
developing.
Although we have sequenced the cancer genome
extensively, and have identified a number of driver
and passenger mutations, we are yet far from having
a map of the full genomic alterations involved in the
onco-pathogenesis of thyroid cancer (Figure 2). We
are, though, capable of patterning the phenotypic
expressions in terms of profiling. Individual tumor
morphology, function and biology are compound results
of mutational changes, and selective activation and/or
deactivation of gene switches. Eventually, the cancer
morphology, or architectural neo-differentiation will
be understood and defined in terms of sets of genes
that are expressed (transcribed) in neoplastic tissues.
Perhaps the “papillary thyroid cancer” assignment based
on morphology, its intricate variations, and perplexing
functional and prognostic associations will be replaced
by gene expression profiles, mathematical abstractions,
with clear indications as to its biologic meaning. We
will, though, continue to refer to the morphology as
part of its complete profile, not a sole indicator of its
prognosis and treatment options. This will also pave the
road to rational treatment actions. The concept of risk
stratification based on traditional parameters will soon
vacate their role for clear molecular markers of noninvasive/focal, invasive/metastatic and systemic stages/
phases of neoplastic disorder.
Truly local/indolent tumors could easily be addressed
with less invasive techniques such as Laser ablation and
Table 3. ThyroSeq v2 panel
Gene mutations
(DNA)

7

Gene fusions
(RNA)

Gene expression (RNA)

BRAF

RET

RET

PGK1

NRAS

TSHR

PPARG

KRT7

HRAS

AKT1

NTRK1

TG

KRAS

TP53

NTRK3

TTF1

PIK3CA

GNAS

BRAF

NIS

PTEN

CTNNB1

ALK

Calcitonin

MTC

TERT

EIF1AX

PTH

Parathyroid

KRT20

Metastatic

Pan-cell

Thyroid cell
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Figure 2. Main mutation mechanisms: Point mutations and chromosome rearrangements
Adapted from Nikiforov YE, Diagnostic pathology and molecular genetics of the thyroid, 2009

has acquired a new method for testing the appropriate
treatment for individual patients; that is molecular
pathology, governed by genomics. The technology is
present and rapidly evolving. The surgeons will determine
the extent of interventions with molecular evidence and
guidance.
The translation of cancer genomics data into clinical
insights will elevate oncology to the next level and usher
in a new era in understanding, diagnosing and treating
cancer. The new evidence in “evidence-based medicine”
is the genomic data.

radiofrequency ablation, at the most by lobectomy. On the
other hand when a potential for metastatic development
is identified, regardless of the tumor size or patient’s
age, the most aggressive approach including complete
thyroidectomy (surgical total thyroidectomy followed by
beta-knife ablation) will be employed. We will not feel
inadequate to explain to an unfortunate patient why
his/her small, supposed to be indolent tumor is taking a
fatal course. We will not record those cases as statistical
misfits. Patient-specific treatment protocols will prevail. A
refined classification scheme based on genomics and its
phenotypic expressions will accurately reflect the biologic
differences between the different morphologic definitions
we use today. Tumor differentiation/de-differentiation, and
clinical behavior of an individual cancer will be defined
by molecular markers, in addition to standard morphopathology. Empiricism in science of medicine and surgery

In god we trust,
All others must bring data.
William Edward Deming
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